Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Toth Financial Advisory Corp

Toth Financial Advisory Corp boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,250 shares of the biopharmaceutical company’s stock after buying an additional 3,750 shares during the quarter. Toth Financial Advisory Corp’s holdings in Catalyst Pharmaceuticals were worth $1,132,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of CPRX. Dimensional Fund Advisors LP boosted its stake in shares of Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after acquiring an additional 263,099 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 4.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after acquiring an additional 50,804 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Catalyst Pharmaceuticals by 47.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock worth $9,577,000 after acquiring an additional 200,370 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 87.1% during the 2nd quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock worth $7,565,000 after acquiring an additional 227,321 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after buying an additional 33,888 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 in the last three months. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.2 %

Shares of Catalyst Pharmaceuticals stock opened at $22.55 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.12 and a fifty-two week high of $24.27. The firm has a market cap of $2.69 billion, a PE ratio of 19.11, a P/E/G ratio of 2.28 and a beta of 0.79. The business’s fifty day moving average is $21.79 and its two-hundred day moving average is $20.45.

Analysts Set New Price Targets

CPRX has been the topic of several recent research reports. Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. HC Wainwright upped their target price on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Finally, Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $32.86.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.